Cardiovascular outcomes of GLP-1RA vs SGLT2i in MASLD and type 2 diabetes: real-world evidence
Main finding · Major adverse cardiovascular and cerebrovascular eventsResult — go to the resultHazard ratio 0.86 95% CI 0.80–0.92Authors' conclusion
Among patients with MASLD and T2D, GLP-1 RA therapy was associated with a lower risk of cardiovascular events than SGLT2is, providing real-world comparative evidence in this population.
Study context
- Population
- Adults with MASLD and T2D initiating GLP-1 RAs or SGLT2is between 2017 and 2025; mean age 58.5 years, 49.7% womenmatched cohort
- Participants
- 52,094 adults
- Exposure
- GLP-1 RA vs SGLT2i
- Outcome
- Major adverse cardiovascular and cerebrovascular events
- Follow-up
- Median 3.0 years
Methodological detailsTriNetX global health research network, propensity score matched, target-trial emulation
- TriNetX global health research network
- Propensity score matched
- Target-trial emulation
Main finding
As reported in the abstract
Hazard ratio
0.86
95% CI 0.80–0.92
P < 0.001
GLP-1 RAsvs SGLT2is
HR 0.86 (95% CI 0.80–0.92); P < 0.001
Observational data: associations, not effects.
Further findings
HF, MI, stroke and all-cause mortality
- Risks of HF, MI, stroke and all-cause mortality also significantly reduced with GLP-1 RAs
Sensitivity analyses
- Results consistent across sensitivity analyses
Original publication
Cardiovascular outcomes of GLP-1RA vs SGLT2i in MASLD and type 2 diabetes: real-world evidence. Diabetes Res Clin Pract. Published 7 March 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →